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Abstract
  
 Cervical cancer is one of the most leading causes of women death. Currently, paclitaxel 
is still one of the main therapeutic regimens for cervical cancer patients. However, some 
patients developed to be paclitaxel-resistant. Hence, studies to find out the novel strategies 
to resolve this problem are important. Generating resistant cancer cell lines can be utilized 
as the potent tool to evaluate the efficacy of any therapeutic agent toward cancer drug-
resistant problems. Current studies describing the methods to establish chemoresistance 
are lacking. Moreover, study in Indonesia conducting chemoresistance in cell line is limited. 
This study was aimed to elaborate the characteristics of HeLa cells during generation of 
paclitaxel-resistant cervical cancer cells. The parental HeLa cells were exposed to an 
escalating concentration of paclitaxel for a long time period. Subsequently, cells were 
divided into two groups for the evaluation of resistance characteristics. The values of 
inhibitory concentration 50 (IC50) and inhibitory concentration 90 (IC90) were analyzed 
using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay. Our data 
showed that the longer exposing periods of paclitaxel, the higher IC50 and IC90 values of HeLa 
cells are. IC90 of paclitaxel in HeLa Pac RB was increased from 69 pM, 440 pM, 2,561 pM and 
10,337 pM on 0th, 1st, 2nd, 3rd and 4th months, respectively.  Interestingly, the resistant cells 
were recovered to be paclitaxel-sensitive when they were not being continuously exposed 
to paclitaxel. In addition, the paclitaxel resistant cells become less sensitive against 5-FU 
but not doxorubicin, cisplatin and etoposide. We were able to generate cervical cancer 
HeLa paclitaxel-resistant cell line. These cell line could potentially be utilized for further 
studies in order to understand the molecular mechanisms of drug resistance in cervical 
cancer and as a tool for cancer drug discovery.
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INTRODUCTION
 Non communicable diseases (NCDs) have 
become one of the most focused health problems 
worldwide. Among all of the NCDs, the most 
common cancer in women is cervical cancer 
(McGuire, 2016). Due to its high level of prevalence 
and mortality rate, cervical cancer becomes a 
cancer that has been discovered intensely through 
numerous studies. Therefore, in order to support 
the reliability of the studies to evaluate therapeutic 
effects toward cervical cancer, a proper tool that 
reflects a certain condition of cervical cancer 
patient’s is needed. 
 Currently, multiple cervical cancer 
treatments available for the patients; surgery, 
radiotherapy, and chemotherapy, in which could 
also be done in combination. The standard 
chemotherapy regimen that has widely given to 
the patients is a combination of cisplatin with 
paclitaxel  (Koh, et al., 2019). As an adjuvant 
therapy, chemotherapy poses an important role as it 
prolongs patients’ survival rate through preventing 
the cancer’s recurrence and metastasis. However, 
some patients are-born-to-be or acquired resistant 
of chemotherapy. The resistance might happen on 
several chemotherapy drugs, in which one of those 
is paclitaxel. Studies to evaluate the mechanism of 
chemotherapy resistance in cervical cancer patients 
had been conducted. The studies showed the overall 
response rate is 29.1%–67% and median overall 
survival is 12.87 months in patients with advanced 
cervical cancer (Peng, et al., 2014; Zhu, et al., 
2016). There are multitude factors contributed to 
the conditions that could potentially lead to the 
development of resistance in which the patient 
has low response to a given treatment (Mansoori, 
et al., 2017). In order to discover the mechanisms 
that establish the resistance of chemotherapy and 
further developing potential drug or substance, a 
cellular model that reflects human’s homeostasis is 
needed. 
 Generating resistant cervical cancer cell 
lines can be utilized as a utility to evaluate the 
efficacy of any therapeutic agents toward cervical 
cancer drug-resistant problems. Methods to 
generate paclitaxel-resistant HeLa cells had been 
developed for years (Bi, et al., 2014; Lee, 2004; 
McDermott, et al., 2014; Peng, et al., 2014). To our 
recent knowledge, there is subtle amount of studies 
described the process of paclitaxel-resistant HeLa 
cells formation. Moreover, there is very limited 
study in Indonesia that utilized the generated 
cells, making this study might carry more benefits 
in addition to the complexity of the techniques. 
Hence, to confirm and establish the techniques is 
important to create an integral part of further studies 
in cervical cancer in Indonesia.
MATERIALS AND METHODS
Cell Culture 
 This study was subjected parental HeLa 
cells from Dr. Hasan Sadikin General Hospital, 
Bandung, Indonesia. HeLa cells were cultured in 
RPMI medium (cat No. 11875093, Gibco, New 
York, USA) supplemented with 10% fetal bovine 
serum (FBS) (cat No. 10270106, Gibco, USA) 
and 1% penicillin-streptomycin, incubated with a 
controlled temperature at 37oC containing 5% CO2. 
Generating Paclitaxel-Resistant HeLa Cells
 The parental HeLa cells were exposed with 
modified escalating concentration in a long period 
of time according to previous study (McDermott, 
et al., 2014). Briefly, after having data of inhibitory 
concentration 50 (IC50) of paclitaxel in the parental 
cells, the cells were treated with IC50 of paclitaxel 
(from Pharmacy Dr. Hasan Sadikin General 
Hospital, Bandung, Indonesia) for three days 
followed by replacing with fresh medium to let the 
cells recovered. The HeLa cells were divided into 4 
groups of exposure; the control (HeLa Parent), IC50 
exposure (HeLa Pac RA), inhibitory concentration 
90 (IC90)  exposure (HeLa Pac RB) and two-fold 
of IC90 exposure (HeLa Pac RC). These groups 
of exposure were done in two until three days 
depends on cells characteristics. If the cells had 
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seen dying microscopically, the culture medium 
was replaced with fresh medium until the cells 
are recovered. The experiment was repeated until 
reaching four months. At the end of each month, 
the cells were being evaluated for its resistance 
towards paclitaxel. The evaluation of the resistance 
characteristic was done through determination of its 
IC50 and IC90 values using (3-[4,5-dimethylthiazol-
2-yl]-2,5 diphenyl tetrazolium bromide (MTT) 
assay, (cat No. M2128, Sigma-Aldrich, Missouri, 
USA). Additionally, after the cells were confirmed 
to become paclitaxel-resistant, some of them were 
cultured without any exposure to paclitaxel for two 
months to understand further characteristic of HeLa 
cervical cancer resistant cells.
Cytotoxic Assay 
 In order to determine the IC50 and IC90 
values as well as cytotoxic effects of tested drugs, 
the cells were exposed to MTT (Meerloo, et al., 
2011). Briefly, the cells were seeded on 96-well plate 
then treated with serial concentrations on the next 
day. After that, the cells were placed in incubator 
for 72 h with 5% CO2 at 370C. Cells contains 
medium with 1% Dimethyl Sulfoxide (DMSO) 
were used as control. The MTT solution was 
added and the mixture was incubated for 4 h. Next, 
DMSO was added to dissolve the formazan crystal. 
Absorbance was measured at the wavelength 550 
nm for percentages of viable cells on treated cells, 
compared to the control cells. 
 In addition to evaluate the characteristic 
of paclitaxel resistance cells, both parental and 
paclitaxel resistance cells were exposed to different 
chemotherapy agents including 5-FU, doxorubicin, 
cisplatin and etoposide. This evaluation was 
aimed to know whether any cross resistant with 
other chemotherapy drugs. All procedures were 
conducted in the laboratory of cell culture and 
cytogenetic, Faculty of Medicine, Universitas 
Padjadjaran, Indonesia.
 Data obtained from MTT assay was 
then analyzed for drug curves, the IC50 and IC90 
value using four-parametric logistic regression 
by SigmaPlot for windows version 12.0 software 
(Systat Software Inc., San Jose, California, USA).
RESULTS
 To evaluate the ability of HeLa cells to 
resist against chemotherapy, we used MTT assay to 
assess cell death after given in serial concentrations. 
Each condition of both parental and paclitaxel 
exposing cells were compared. The result showed 
that the higher of resistance level of the cancer 
cells the higher of their threshold to be able to 
reach the maximum number of cell death (Figure 
1). Moreover, as the level of HeLa cell paclitaxel-
resistant progressed increasingly in each month, the 
results showed an increased value of the IC50 and 
IC90 of the HeLa Pac RB. Upon exposing impulse 
concentration of paclitaxel, the IC90 of paclitaxel in 
HeLa Pac RB was increased from 69 pM, 440 pM, 
2,561 pM and 10,337 pM on 0th, 1st, 2nd, 3rd and 4th 
months, respectively. (Figure 2). 
Figure 1. Drug curves of paclitaxel in HeLa cells af-
ter 3 months exposing different conditions of 
paclitaxel for generating HeLa paclitaxel re-
sistant cells. HeLa Parent=parental HeLa cells. 
HeLa Pac RA=impulse exposing of IC50 concen-
tration. HeLa Pac RB=impulse exposing of IC90 
concentration. HeLa Pac RC=impulse exposing 
of two-fold of IC90 concentration.
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Figure 2. Both IC50 and IC90 increase following the 
exposing paclitaxel in HeLa Pac RB cells.
 Subsequently, to observe whether the resis-
tance occur permanently or temporarily, we stopped 
paclitaxel treatment for some resistant cells. In-
triguingly, the experiment showed that the resistant 
cells become more sensitive to paclitaxel if the cells 
were not being treated (Figure 3). 
 Finally, we evaluate sensitivity  of  pacli-
taxel-resistant HeLa cells to other chemotherapeu-
tic agents. We treated both parental HeLa cells and 
the paclitaxel-resistant HeLa cells with other con-
ventional chemotherapeutic agents (5-FU, doxoru-
Figure 3. De-escalation of induction drug sensitizes 
the resistant HeLa Pac RB cells. After 2 months 
exposed with paclitaxel, the HeLa Pac RB cells 
and HeLa Pac RB-1 cells were exposed and not 
exposed, respectively, with paclitaxel for an-
other 2 months.
bicin, cisplatin and etoposide). The result showed 
the paclitaxel-resistant HeLa cells become less sen-
sitive against 5-FU but not doxorubicin, cisplatin 
and etoposide (Figure 4).
Figure 4. Different cytotoxic response of che-
motherapeutics in parental HeLa  cells  and 
paclitaxel resistan ce HeLa  cells. *)p<0.05; 
**)p<0.01, ***)p<0.001.
DISCUSSION
 Paclitaxel is one of the chemotherapeutic 
agent that belongs to class of taxane and was pro-
duced from pacific pine trees (Taxus brevifolia) and 
European pine trees (Taxus baccata) (Soca-Cha-
fre, et al., 2011). Paclitaxel has also known for its 
anticancer effects against various malignancies 
such as cervical cancer, ovarian cancer, breast can-
cer, lung cancer and other cancer types. The drug 
has a high affinity to bind with β-tubulin, thereby 
allowing  polymerization   of  tubulin  cells  leading 
to disruption  of  decomposition  of  microtubules 
(Mariani, et al., 2015;  Zhang, et al., 2012). This 
process leads to breakdown of mitosis processing, 
causing cancer cells apoptosis or cellular death. 
Moreover, paclitaxel has other mechanism by inac-
tivating bcl-2 protein which also leads to cellular 
apoptosis (Demidenko, et al., 2008).
 Paclitaxel has been used as chemotherapy 
regiments for cervical cancer patients. Unfortu-
nately, during treatment some of the patients are 
developing resistance to the drug. Therefore, re-
search to explore mechanisms of cancer cells’ che-
moresistance had also widely conducted to resolve 
the problems. There are numerous mechanisms of 
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cancer chemoresistance that have been discovered. 
The main mechanism of paclitaxel-resistant can-
cer cells is the overexpression of P-glycoprotein 
(P-gp) that works as a drug efflux pump. The P-gp 
will pump out the ingested drug throughout the cell. 
However, the use of P-gp inhibitors are sometimes 
ineffective or even toxic at the optimum dose to in-
terfere P-gp functions (de Figueiredo-Pontes, et al., 
2008). Other possible mechanisms of cancer cells’ 
resistance to paclitaxel are: alteration   of  the  drug 
affinity to bind with microtubules, alteration of tu-
bulin structure and deregulation of cancer cell cy-
cle (Dumontet and Jordan, 2010; Kavallaris, 2010). 
Therefore, the mechanisms of cancer cells’ resis-
tance to  paclitaxel, as tubulin binding agent, are 
complex and remain unclear.
 The parental HeLa cervical cancer cells 
were being exposed to high concentration of pacli-
taxel continuously for a long time period. The cells 
which successfully recovered after being exposed 
with higher IC concentration were considered as 
paclitaxel-resistant cells. Figure 1 showed the HeLa 
Pac RB and HeLa Pac RC have level of resistance 
on IC90 and two-fold IC90 respectively, and they 
never reach the rate of the cell death as HeLa paren-
tal cells. Furthermore, data from Figure 2 showed 
the longer cells were being exposed, the higher their 
IC50 and IC90 values. The most likely explanation to 
this finding is the cells were successfully adapted 
by overexpressing P-gp to pump out the ingested 
drug  throughout  the  cell  (Zhou, et al., 2019). 
Another possible explanation is the cells might spe-
cifically alter its tubulin structure, thus disturbing 
paclitaxel's affinity in tubulin binding. Therefore, 
the concentration of the drug inside resistant cell 
could not reach its maximum therapeutic effect.
 Another interesting finding from our study 
is the resistant HeLa cells which not exposed to pa-
clitaxel after two months (HeLa Pac RB-1), were 
regain their sensitivity to paclitaxel as their prior 
condition (Figure 3). Although the exact mecha-
nisms of this finding has not been fully understood, 
we hypothesized a mechanisms based on study by 
Peng, et al. which proposed a novel paclitaxel-re-
sistant pathway involving Warburg effect acti-
vated Hypoxia-inducible factor 1-alpha-mediated 
(HIF1-α-mediated) signaling induced autophagy 
(Peng, et al., 2014). It is well known that Warburg 
effect on cancer cell explain the cells’ preference 
to solely use glycolysis as their energy source. 
Glycolysis end product, lactate and pyruvate, will 
up-regulate HIF1-α expression which then benefit 
cancer cell to undergo malignant transformation, 
metastasis, and develop chemo-resistance. (Lu, et 
al., 2002) Overexpression of HIF1-α will increase 
cancer cells’ level of autophagy and creating pacli-
taxel-resistant cancer cell. Contrarily, if autophagy 
is  inhibited, sensitivity  to  paclitaxel  will be  re-
covered (Peng, et al., 2014). Other study also con-
firmed that induction of autophagy correlate with 
paclitaxel resistance in cervical cancer. (Park, et 
al., 2018; Zou, et al., 2018) Another mechanism 
found to be correlated with acquired paclitaxel re-
sistance is overexpression of microRNA miR-375. 
Paclitaxel up-regulates miR-375 expression during 
continuous exposure with the drugs, miR-375 will 
over-expressed and consequently, the chemo-resis-
tance is developed. After discontinuation of pacli-
taxel in chemo-resistant cell, there was a gradually 
decreasing expression of miR-375 and its level 
of expression was restored to the level before pa-
clitaxel administration. (Shen, et al., 2014)  This 
finding  may  partially  explain our finding, further 
study with several molecular markers are needed to 
explain mechanisms of paclitaxel resistance in cer-
vical cancer.
CONCLUSION
 In conclusion, HeLa parental cells that were 
being exposed in escalated concentration for a long 
period developed  resistance to the chemotherapy. 
The duration of the constant exposure is positively 
correlated with the level of resistance. Also, resis-
tant cancer cells will back to be more sensitive if the 
exposures were not being continued. 
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